Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2007;29(4):441-6.
doi: 10.1080/08860220701260511.

Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy

Yoshio Horita  1 , Masato Tadokoro, Kouichi Taura, Ryuichi Ashida, Mayumi Hiu, Takashi Taguchi, Akira Furusu, Shigeru Kohno
Affiliations
Randomized Controlled Trial

Prednisolone co-administered with losartan confers renoprotection in patients with IgA nephropathy

Yoshio Horita et al. Ren Fail. 2007.

Abstract

Background: Treatment options for progressive IgA nephropathy are limited.

Methods: We performed a small, randomized controlled trial to evaluate the effects of prednisolone (PSL, 30 mg/dL, gradually tapered to 5 mg/dL over two years) plus 50 mg/day of losartan (LST, an angiotensin II receptor blocker) or PSL alone on IgA nephropathy. We separated 38 patients (age, 33 +/- 11 years; creatinine clearance, 103 +/- 31 mL/min; proteinuria, 1.6 +/- 0.5 g/day) into two groups that were treated with either PSL plus LST or PSL alone, and compared the proteinuria and creatinine clearance after two years. Baseline and histopathological data did not significantly differ between the two groups.

Results: Two years of treatment in both groups significantly decreased proteinuria compared with baseline, and PSL plus LST (from 1.6 +/- 0.6 to 0.3 +/- 0.1 g/day, p < 0.05) was more effective than PSL alone (from 1.6 +/- 0.3 to 0.5 +/- 0.1 g/day, p < 0.05). Creatinine clearance in both groups was similar at the start of study but significantly differed at the end of the study (PSL plus LST, 104.3 +/- 36.4 to 100.4 +/- 38.9 mL/min; PSL alone, 103.4 +/- 28.5 to 84.8 +/- 34.3 mL/min, p < 0.05).

Conclusions: Combined therapy with PSL plus LST appears to be more effective than PSL alone in reducing proteinuria and protecting renal function in patients with IgA nephropathy.

PubMed Disclaimer

Figures

Figure 1
Figure 1
Blood pressure levels between the two groups. *Compared with baseline, p < 0.01; **compared with baseline, p < 0.05; #comparison between the PSL + LST group and PSL-alone group, p < 0.05. Abbreviations: PSL = prednisolone; LST = losartan.
Figure 2
Figure 2
Creatinine clearance levels between the two groups. *Compared with baseline, p < 0.05. Abbreviation: Ccr=creatinine clearance.
Figure 3
Figure 3
Proteinuria levels between the two groups. *Compared with baseline, p < 0.01; **compared with baseline, p < 0.01; #comparison between the PSL + LST group and PSL-alone group, p < 0.05. Abbreviations: PSL = prednisolone; LST = losartan.
See this image and copyright information in PMC

References

    1. D'Amico G. The commonest glomerulonephritis in the world: IgA nephropathy. Q J Med. 1987;64:709–727. - PubMed
    1. Kobayashi Y, Tateno S, Hiki Y, Shigematsu H. IgA nephropathy: Prognostic significance of proteinuria and histological alteration. Nephron. 1983;34:146–153. - PubMed
    1. Radford MG, Jr, Donardio JV, Jr, Bergstralh EJ, Grande JP. Predicting renal outcome in IgA nephropathy. J Am Soc Nephrol. 1997;8:199–207. - PubMed
    1. Maschio G, Alberti D, Janin G, et al. Effect of the angiotensin-converting enzyme inhibitor benazepril on the progression of chronic insufficiency. The angiotensin-converting-enzyme inhibition in progressive renal insufficiency study group. N Engl J Med. 1996;334:939–945. - PubMed
    1. Maschio G, Alberti D, Locatelli F, et al. Angiotensin-converting enzyme inhibitors and kidney protection: the AIPRI trial. The ACE inhibition in Progressive Renal Insufficiency (AIPRI) Study Group. J Cardiovasc Pharmacol. 1999;33(Suppl. 1):S16–S20. - PubMed

Publication types